Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer
Abstract
Small-cell neuroendocrine prostate cancer (SCNPC) exhibits an aggressive clinical course and incidence rates seem to be increasing following resistance to potent androgen receptor (AR) antagonists. Currently, treatment options are limited and few model systems are available to identify new approaches for treatment. We sought to evaluate commonalities between SCNPC and other aggressive neuroendocrine carcinomas to identify therapeutic targets.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Apr 01, 2020
- Source ID
- 10.1158/1078-0432.ccr-19-0775
Entities
People
- Alexandra N. Corella
- Arja Kaipainen
- Colm Morrissey
- Daniel Sondheim
- David MacPherson
- Eva Corey
- Holly M. Nguyen
- Ilsa M. Coleman
- Jared M. Lucas
- John K Lee
- Lawrence D. True
- Lisha G. Brown
- Ma Victoria Andrea Cabiliza Ordonio
- Paul Nghiem
- Peter S Nelson
- Roman Gulati
Organizations
- Fred Hutchinson Cancer Center
- National Institutes of Health
- United States Department of Defense
- University of Washington